[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the 2 alternatives as equivalent therapeutic alternatives.PMID:37845105 | DOI:10.1016/j.farma.2023.09.008 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 16, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the 2 alternatives as equivalent therapeutic alternatives.PMID:37845105 | DOI:10.1016/j.farma.2023.09.008 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 16, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the 2 alternatives as equivalent therapeutic alternatives.PMID:37845105 | DOI:10.1016/j.farma.2023.09.008 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 16, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
We report the case of a 71-year-old male, diagnosed with systemic AL kappa amyloidosis and MZL, receiving third-generation CAR T cell therapy targeting CD19. Prior treatment included bendamustine/rituximab and cyclophosphamide/ dexamethasone with subsequent autologous stem cell transplantation. CAR T application was well tolerated despite heart and kidney amyloid manifestations, and only early low-grade procedure-specific toxicities were observed. A continuous decrease in IgM, kappa light chains and kappa-to-lambda light chain difference was observed in the patient from day + 30 on, resulting in a deep hematological respon...
Source: Cell Research - October 14, 2023 Category: Cytology Authors: Felix Korell Stefan Sch önland Anita Schmitt Madelaine Jansen Kiavasch Farid Carsten M üller-Tidow Peter Dreger Michael Schmitt Ute Hegenbart Source Type: research
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
Blood Cancer Journal, Published online: 13 October 2023; doi:10.1038/s41408-023-00929-0Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 13, 2023 Category: Hematology Authors: Surbhi Sidana Hitomi Hosoya Alexandria Jensen Lawrence Liu Anmol Goyal Vanna Hovanky Bita Sahaf Sushma Bharadwaj Theresa Latchford Sally Arai Sheryl Leahy Matthew Mei Lihua E. Budde Lori S. Muffly Matthew J. Frank Saurabh Dahiya Myo Htut David Miklos Mura Source Type: research
Bendamustine/obinutuzumab/rituximab
(Source: Reactions Weekly)
Source: Reactions Weekly - October 1, 2023 Category: Drugs & Pharmacology Source Type: research
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557. Online ahead of print.ABSTRACTFollicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R/R) FL, many patients still die from progressive disease or treatment-related toxicities. In the phase Ib/II GO29365 study (NCT02257567), the safety and efficacy of polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) versus BR alone, and polatuzumab vedotin plus bendamustine and obinutuzumab (Pola-BG) as a single-arm cohort were evaluated in pa...
Source: Haematologica - September 28, 2023 Category: Hematology Authors: Christopher R Flowers Matthew J Matasar Alex F Herrera Mark Hertzberg Sarit Assouline Judit Demeter Andrew McMillan Amitkumar Mehta Stephen Opat Marek Trn ňný Lisa Musick Jamie Hirata Annie Yang Laurie H Sehn Source Type: research
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557. Online ahead of print.ABSTRACTFollicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R/R) FL, many patients still die from progressive disease or treatment-related toxicities. In the phase Ib/II GO29365 study (NCT02257567), the safety and efficacy of polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) versus BR alone, and polatuzumab vedotin plus bendamustine and obinutuzumab (Pola-BG) as a single-arm cohort were evaluated in pa...
Source: Haematologica - September 28, 2023 Category: Hematology Authors: Christopher R Flowers Matthew J Matasar Alex F Herrera Mark Hertzberg Sarit Assouline Judit Demeter Andrew McMillan Amitkumar Mehta Stephen Opat Marek Trn ňný Lisa Musick Jamie Hirata Annie Yang Laurie H Sehn Source Type: research
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557. Online ahead of print.ABSTRACTFollicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R/R) FL, many patients still die from progressive disease or treatment-related toxicities. In the phase Ib/II GO29365 study (NCT02257567), the safety and efficacy of polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) versus BR alone, and polatuzumab vedotin plus bendamustine and obinutuzumab (Pola-BG) as a single-arm cohort were evaluated in pa...
Source: Haematologica - September 28, 2023 Category: Hematology Authors: Christopher R Flowers Matthew J Matasar Alex F Herrera Mark Hertzberg Sarit Assouline Judit Demeter Andrew McMillan Amitkumar Mehta Stephen Opat Marek Trn ňný Lisa Musick Jamie Hirata Annie Yang Laurie H Sehn Source Type: research
